Abstract | BACKGROUND/AIM: PATIENTS AND METHODS: We analyzed patients from two prospective trials, in which capecitabine/ oxaliplatin ( XELOX, 8 cycles; n=51) and S-1/ oxaliplatin [SOX, continuous (SOX-C, n=50), or intermittent (discontinuation after cycle 6 and restart on progression, SOX-I, n=50)] were administered. We compared severity ( splenomegaly, thrombocytopenia, liver enzyme levels, and hepatic parenchymal heterogeneity), clinical significance (delay or dose-reduction of chemotherapy), and reversibility of SOS ( splenomegaly and thrombocytopenia after stopping chemotherapy) between SOX and XELOX in gastric cancer patients. RESULTS: CONCLUSION:
|
Authors | Eo Jin Kim, Moonho Kim, Seyoung Seo, Mi-Jung Kim, Min Ju Kim, Sook Ryun Park |
Journal | Anticancer research
(Anticancer Res)
Vol. 41
Issue 1
Pg. 391-402
(Jan 2021)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 33419836
(Publication Type: Journal Article)
|
Copyright | Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Biomarkers
- Drug Combinations
- Oxaliplatin
- S 1 (combination)
- Tegafur
- Oxonic Acid
- Capecitabine
|
Topics |
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Biomarkers
- Capecitabine
(administration & dosage)
- Disease Management
- Drug Combinations
- Female
- Hepatic Veno-Occlusive Disease
(diagnosis, epidemiology, etiology, therapy)
- Humans
- Incidence
- Liver Function Tests
- Male
- Middle Aged
- Oxaliplatin
(administration & dosage)
- Oxonic Acid
(administration & dosage)
- Retrospective Studies
- Spleen
(pathology)
- Splenectomy
- Stomach Neoplasms
(complications, drug therapy)
- Tegafur
(administration & dosage)
- Treatment Outcome
|